Published by Josh White on 18th March 2024
(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.
URL: http://www.digitallook.com/dl/news/story/34161749/...